Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions
- 1 January 2003
- journal article
- research article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 41 (1) , 26-32
- https://doi.org/10.1016/s0735-1097(02)02666-9
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trialsThe Lancet, 2002
- Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non–ST-Segment-Elevation Acute Coronary SyndromesCirculation, 2001
- Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary interventionThe American Journal of Cardiology, 2001
- Sustained Suppression of Ischemic Complications of Coronary Intervention by Platelet GP IIb/IIIa Blockade With AbciximabCirculation, 1999
- Clinical Outcomes of Therapeutic Agents That Block the Platelet Glycoprotein IIb/IIIa Integrin in Ischemic Heart DiseaseCirculation, 1998
- Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial InfarctionCirculation, 1998
- Long-term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin β3 Blockade With Percutaneous Coronary InterventionJAMA, 1997
- Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE studyThe Lancet, 1997
- Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six monthsThe Lancet, 1994
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994